Who we are
About Alesta Therapeutics
Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules for rare diseases. The company’s lead asset, ALE1, is being developed for hypophosphatasia (HPP), a rare genetic disorder with significant unmet needs. Alesta is also advancing ALE2, a promising candidate to treat Charcot-Marie-Tooth (CMT) disease.
OUR team
Investors
Alesta Therapeutics was incorporated by Droia Ventures and is supported by a network of esteemed partners. Together, we are committed to advancing innovative treatments that can make a significant difference in the lives of patients.
OUR team
Management team
Ilan Ganot
(Solid Biosciences, JP Morgan)
CEO
Matthias Van Woensel
PhD
(Droia Ventures)
CSO
Benit Maru
MBChB PhD
(AveXis/Novartis, Taysha)
CMO
Jakub Swiercz
(iTeos, Epics)
Vice President Research and Development
Laurie Smaldone Alsup
MD
(Bristol Meyers Squibb)
Global Regulatory Lead
Bjorn Carlsson
PhD
(Swedish Medicines Agency, EMA)
CMC & Nonclinical Regulatory
Board of directors
Janwillem Naesens
(Droia Ventures)
Laura Brass
PhD
(Novartis Venture Fund)
Dan Estes
PhD
(Frazier Life Sciences)
Luc Dochez
(Droia Ventures)
Chairman
Ilan Ganot
(Solid Biosciences, JP Morgan)
CEO
Get in touch
Contact us for more information !
For inquiries or more information, please reach out to us. We’re here to help!